Clonal Hematopoiesis & Aging Genomes
Somatic mutations accumulate. Some matter for cancer, some for cardiovascular disease, some for neither.
What's covered
- T01CHIP definition: somatic driver, VAF ≥2%, no overt malignancy
- T02Top genes: DNMT3A, TET2, ASXL1, JAK2, TP53, SF3B1, SRSF2
- T03Cardiovascular risk: TET2-driven inflammasome, IL-1β, atherosclerosis
- T04Progression risks: CCUS → MDS / AML stratification (CHRS score)
- T05Treatment-related CH and AML risk after PARP / chemo
- T06Mosaic chromosomal alterations (mCAs), Y-loss, X-loss
By the end of this module you will be able to
- L01Define CHIP, CCUS, and ICUS and their distinct progression risks.
- L02Explain the TET2/IL-1β mechanistic link between CHIP and atherosclerosis.
- L03Apply the Clonal Hematopoiesis Risk Score (CHRS) to a patient with a hematology referral.
What you should walk away believing
- CHIP carries an absolute hematologic-malignancy risk of ~0.5–1%/year overall — but CHRS-stratified high-risk patients can reach >50% 10-year transformation risk.
- CHIP is independently associated with a ~2× increase in incident CHD; the mechanism (TET2 → NLRP3 inflammasome) supports targeted anti-inflammatory therapy concepts (CANTOS post-hoc).
- Y-chromosome loss in hematopoietic cells affects ~40% of men >70 and is associated with cardiovascular and Alzheimer's risk.
- Treatment-related CHIP (post-PARP, post-platinum) is now a recognized driver of secondary AML — informs PARP-inhibitor selection in long-survival populations.
What this means at your level
As we age, our blood-forming stem cells accumulate mutations. Sometimes a single clone expands enough to become detectable in routine blood tests. This 'clonal hematopoiesis' rarely progresses to leukemia, but it does increase the risk of cardiovascular disease through inflammation. It also confounds liquid-biopsy interpretation in cancer.
CHIP is most often discovered incidentally on tumor or liquid-biopsy panels. Frame the finding for the patient: small but real cardiovascular risk increase, small per-year malignancy risk, no current targeted intervention. Use CHRS to stratify referral urgency. Consider that PARP inhibitor exposure increases AML risk; be careful in long-prognosis populations.
CHIP, CCUS, ICUS are now distinct entities with separate WHO/ICC criteria. The CHRS score (Weeks et al. NEJM Evid 2023) integrates VAF, mutation type, and CBC features to stratify progression. Anti-inflammatory therapies in CHIP-positive CV-risk populations are an active translational target (anakinra, ziltivekimab).
What the data say
Test yourself
Key terms & abbreviations
- CHIPClonal Hematopoiesis of Indeterminate Potential
- Somatic driver mutation at VAF ≥2% in blood without cytopenias or hematologic diagnosis.
- CCUSClonal Cytopenia of Undetermined Significance
- Persistent unexplained cytopenia plus a clonal somatic mutation; higher MDS progression risk than CHIP.
- CHRSClonal Hematopoiesis Risk Score
- Validated 8-component score stratifying 10-year myeloid neoplasm risk (Weeks 2023).
- mCAMosaic Chromosomal Alteration
- Large somatic CNVs detectable in blood; LOY (loss of Y) is the most prevalent in older men.
Anchor references
- Age-related clonal hematopoiesis associated with adverse outcomes — Jaiswal et al., NEJM 2014
- Prediction of risk of myeloid malignancy in clonal hematopoiesis (CHRS) — Weeks et al., NEJM Evid 2023